Aclaris reports Q2 2026 results, ATI-052 Phase 1a data and reaffirmed timelines
Aclaris says cash of $170.6 million plus a recent $40.2 million stock sale should fund operations through the end of 2028 as multiple readouts approach.
Aclaris Therapeutics announced second quarter 2026 financial results and a pipeline update on August 6, 2026. The company reported positive full top line results from a Phase 1a single and multiple ascending dose trial of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, saying the drug was well tolerated with a favorable safety profile, and that its pharmacokinetic duration and pharmacodynamic effect supported the potential for up to quarterly dosing.1
Aclaris reaffirmed it expects top line results in the second half of 2026 from two ongoing Phase 1b proof-of-concept trials of ATI-052 in atopic dermatitis and asthma.1 The company also confirmed plans to start a Phase 2b program for ATI-052 in the fourth quarter of 2026, beginning with an asthma trial, and said it now also expects to begin startup activities for a Phase 2b trial in atopic dermatitis and a proof-of-concept trial in eosinophilic esophagitis.1
For bosakitug, its anti-TSLP monoclonal antibody, Aclaris said enrollment is complete in the randomized, double-blind, placebo-controlled Phase 2 trial in 109 atopic dermatitis patients, with top line results still expected in the fourth quarter of 2026.1
In its ITK franchise, Aclaris plans to initiate a multi-part Phase 2b trial of modzatinib in lichen planus in the fourth quarter of 2026, an indication the company said currently has no approved therapies.1 The company also said it remains on track to file an IND for ATI-9494, its dual ITK/TXK inhibitor, in the fourth quarter of 2026.1 New preclinical data presented at a FASEB conference showed, according to the company, that "ATI-9494 demonstrated potency up to 25 times greater than soquelitinib (CPI-818) across multiple biochemical and functional cellular assays."
On finances, Aclaris held $170.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, up from $151.4 million at the end of 2025.1 After the quarter closed, the company sold 7.3 million shares under its at-the-market agreement for $40.2 million in gross proceeds.1 Aclaris said its cash position should fund operations through the end of 2028, excluding any future financing or business development activity.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.